Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167824 | 0.83 | CYP2D6 (0.50) | CYP2D6KDM4E | |
| SCHEMBL25082500 | 0.83 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL10313055 | 0.80 | CYP2D6 (0.41) | CYP2D6 | |
| SCHEMBL14450798 | 0.80 | — | — | |
| SCHEMBL7722438 | 0.79 | CYP2D6 (0.45) | CYP2D6KDM4E | |
| SCHEMBL12314824 | 0.79 | CYP2D6 (0.45) | CYP2D6KDM4E | |
| SCHEMBL8395185 | 0.78 | — | — | |
| SCHEMBL598372 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL22488 | 0.77 | CYP2D6 (0.43) | CYP2D6KDM4E | |
| SCHEMBL21236172 | 0.77 | CYP2D6 (0.30) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163165-A1 | LOW MOLECULAR WEIGHT PRODUCTS AND USE THEREOF AS REVERSIBLE OR PERMANENT LOW-TEMPERATURE CROSSLINKING AGENT IN DIELS-ALDER REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2014-06-12 | — | — | US | claimed |
| US-7557242-B2 | Multistage continuous preparation of cycloaliphatic disocyanates | DEGUSSA AG (DE) | 2009-07-07 | — | — | US | claimed |
| US-20050250960-A1 | Phosgene-free; reacting a cycloaliphatic diamine with a carbonic acid derivative and an alcohol to produce a cycloaliphatic diurethane, distillation, thermally cleaving the cycloaliphatic diurethane to produce a cycloaliphatic diisocyanate, recycling reurethanization product directly into the low-boiler | DEGUSSA AG (DE) | 2005-11-10 | — | — | US | claimed |
| WO-2020210117-A1 | STEROIDS WITH ALTERED PHARMACOKINETIC PROPERTIES AND METHODS OF USE THEREOF | ATHENEN THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| CN-110099932-A | Resin combination | 诺佛赛特有限责任公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-109071745-A | Cyanate ester compound, method for producing same, resin composition, cured product, prepreg, sealing material, fiber-reinforced composite material, adhesive, metal foil-clad laminate, resin sheet, and printed wiring board | 三菱瓦斯化学株式会社 | 2018-12-21 | — | — | CN | disclosed |
| US-20180217498-A1 | PHOTOACTIVABLE NITROGEN BASES | BASF SE (DE) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163165-A1 | LOW MOLECULAR WEIGHT PRODUCTS AND USE THEREOF AS REVERSIBLE OR PERMANENT LOW-TEMPERATURE CROSSLINKING AGENT IN DIELS-ALDER REACTIONS | DCLRE1A, ACP1, DERA | CYP2D6 4462/4885KDM4E 2104/4885 |
| US-20180217498-A1 | PHOTOACTIVABLE NITROGEN BASES | CBR1, NR0B1, NR0B2 | CYP2D6 551/4885KDM4E 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.